Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 162 Triple Negative Breast Neoplasms 161 Carcinoma, Non-Small-Cell Lung 59 Melanoma 44 Ovarian Neoplasms 42 Colorectal Neoplasms 37 Carcinoma, Renal Cell 36 Squamous Cell Carcinoma of Head and Neck 33 Pancreatic Neoplasms 29 Stomach Neoplasms 28 Neoplasm Metastasis 26 Uterine Cervical Neoplasms 24 Neoplasms 24 Endometrial Neoplasms 23 Lung Neoplasms 19 Head and Neck Neoplasms 19 Esophageal Neoplasms 18 Carcinoma, Transitional Cell 18 Carcinoma, Hepatocellular 16 Urinary Bladder Neoplasms 14 Prostatic Neoplasms 14 Small Cell Lung Carcinoma 13 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Sarcoma 10 Mesothelioma 9 Kidney Neoplasms 9 Cholangiocarcinoma 9 Carcinoma, Ovarian Epithelial 9 Carcinoma, Merkel Cell 9 Fallopian Tube Neoplasms 8

Interventions

Tamoxifen 4 Exercise 3 pyrotinib 2 abemaciclib 2 Paclitaxel 2 Metformin 2 Letrozole 2 Cyclophosphamide 2 Control Groups 2 Capecitabine 2 Bupivacaine 2 Aromatase Inhibitors 2 pembrolizumab 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 palbociclib 1 iniparib 1 exemestane 1 durvalumab 1 darolutamide 1 Yoga 1 Waiting Lists 1 Vitamin D 1 Tumor Burden 1 Tretinoin 1 Trastuzumab 1 Tocopherols 1 Thioctic Acid 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Female × pembrolizumab × Breast × Clear all

NCT03879174 2019-03-18

Pembro

Mediclinic Middle East

Phase 2 Unknown

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡